文献速递其他结缔组织病

弥漫性皮肤型系统性硬化症自身抗体亚群临床差异的分子基础

Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis.
PubMed 文献 · Ann Rheum Dis · 2021-07-06

该研究对52例系统性硬化症(SSc)患者及16名健康对照进行血液和皮肤的高维转录组与蛋白质组分析,旨在揭示SSc特异性自身抗体定义的弥漫性皮肤型SSc亚群间的分子差异。研究发现基于皮肤基因表达和血清蛋白分析可界定反映临床亚群的分子谱,且抗拓扑异构酶-1抗体与抗RNA聚合酶III抗体特异性与纤维化血清标志物的显著不同纵向变化及 divergent 基因表达谱相关。结论提示ANA亚群间存在致病性差异,支持在临床试验中按ANA抗体亚型对SSc病例进行分层。

要点

  • 皮肤基因表达和血清蛋白分析可区分反映临床亚群的SSc分子谱。
  • 抗拓扑异构酶-1与抗RNA聚合酶III抗体亚群在纤维化血清标志物纵向变化上差异显著。
  • ANA亚群间存在致病性差异,支持临床试验按抗体亚型分层。

核心结论

  • SSc基于ANA的亚群间存在分子和致病性差异,支持按抗体亚型进行临床分层。

研究设计与样本

  • 对52例SSc患者和16名健康对照进行血液和皮肤的高维转录组与蛋白质组分析。

主要发现

  • 皮肤基因表达和血清蛋白分析界定了反映临床亚群的SSc分子谱。
  • 抗拓扑异构酶-1抗体和抗RNA聚合酶III抗体特异性与纤维化血清标志物的显著不同纵向变化相关。
  • 两种抗体特异性与不同的基因表达谱相关。
  • 个体患者通路分析定义了重叠和不同的疾病过程。

临床怎么用

  • 在临床试验中可按ANA抗体亚型对SSc病例进行分层。
  • ANA亚群差异可能解释针对特定致病机制的试验在不同亚群中结局不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Clinical heterogeneity is a cardinal feature of systemic sclerosis (SSc). Hallmark SSc autoantibodies are central to diagnosis and associate with distinct patterns of skin-based and organ-based complications. Understanding molecular differences between patients will benefit clinical practice and research and give insight into pathogenesis of the disease. We aimed to improve understanding of the molecular differences between key diffuse cutaneous SSc subgroups as defined by their SSc-specific autoantibodies METHODS: We have used high-dimensional transcriptional and proteomic analysis of blood and the skin in a well-characterised cohort of SSc (n=52) and healthy controls (n=16) to understand the molecular basis of clinical diversity in SSc and explore differences between the hallmark antinuclear autoantibody (ANA) reactivities. RESULTS: Our data define a molecular spectrum of SSc based on skin gene expression and serum protein analysis, reflecting recognised clinical subgroups. Moreover, we show that antitopoisomerase-1 antibodies and anti-RNA polymerase III antibodies specificities associate with remarkably different longitudinal change in serum protein markers of fibrosis and divergent gene expression profiles. Overlapping and distinct disease processes are defined using individual patient pathway analysis. CONCLUSIONS: Our findings provide insight into clinical diversity and imply pathogenetic differences between ANA-based subgroups. This supports stratification of SSc cases by ANA antibody subtype in clinical trials and may explain different outcomes across ANA subgroups in trials targeting specific pathogenic mechanisms.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Clark KEN, Campochiaro C, Csomor E, et al. Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2021. PMID: 34230031. doi:10.1136/annrheumdis-2021-220402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。